MA27289A1 - Composition comprenant un inhibiteur de l'absorption du cholesterol, un inhibiteur de la hmg-coa reductase et un agent stabilisant. - Google Patents

Composition comprenant un inhibiteur de l'absorption du cholesterol, un inhibiteur de la hmg-coa reductase et un agent stabilisant.

Info

Publication number
MA27289A1
MA27289A1 MA28095A MA28095A MA27289A1 MA 27289 A1 MA27289 A1 MA 27289A1 MA 28095 A MA28095 A MA 28095A MA 28095 A MA28095 A MA 28095A MA 27289 A1 MA27289 A1 MA 27289A1
Authority
MA
Morocco
Prior art keywords
inhibitor
hmg
composition
coa reductase
cholesterol absorption
Prior art date
Application number
MA28095A
Other languages
English (en)
Inventor
William D Moore
Shaun Fitzpatrick
Christian Seiler
Robert Saklatvala
Catherine R Petts
Wing-Kee Philip Cho
Original Assignee
Merck Sharp & Dohme
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27289(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Schering Corp filed Critical Merck Sharp & Dohme
Publication of MA27289A1 publication Critical patent/MA27289A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention fournit une composition pharmaceutique composée d'un inhibiteur de l'absorption du cholestérol et d'un inhibiteur de la HMG-CoA réductase, un ou plusieurs antioxydants, de la cellulose microcristalline, de l'hydroxypropyl-méthylcellulose, du stéarate de magnésium et du lactose. Il n'est pas nécessaire que la composition contienne de l'acide ascorbique pour obtenir une stabilité souhaitable.
MA28095A 2002-07-26 2005-02-11 Composition comprenant un inhibiteur de l'absorption du cholesterol, un inhibiteur de la hmg-coa reductase et un agent stabilisant. MA27289A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39869102P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
MA27289A1 true MA27289A1 (fr) 2005-04-01

Family

ID=31188454

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28095A MA27289A1 (fr) 2002-07-26 2005-02-11 Composition comprenant un inhibiteur de l'absorption du cholesterol, un inhibiteur de la hmg-coa reductase et un agent stabilisant.

Country Status (38)

Country Link
US (4) US7229982B2 (fr)
EP (2) EP1531805B1 (fr)
JP (2) JP2005538104A (fr)
KR (2) KR20050045993A (fr)
CN (2) CN101069684A (fr)
AR (2) AR040588A1 (fr)
AT (1) ATE393628T1 (fr)
AU (2) AU2003261217B2 (fr)
BR (1) BR0312933A (fr)
CA (1) CA2493076A1 (fr)
CR (1) CR9767A (fr)
DE (1) DE60320652T2 (fr)
DK (1) DK1531805T3 (fr)
EA (1) EA008888B1 (fr)
EC (2) ECSP055573A (fr)
ES (1) ES2303603T3 (fr)
GE (1) GEP20084443B (fr)
GT (2) GT200300149A (fr)
HR (2) HRP20080518A2 (fr)
IL (2) IL166279A0 (fr)
IS (1) IS7637A (fr)
MA (1) MA27289A1 (fr)
ME (3) ME00207B (fr)
MX (1) MXPA05001004A (fr)
MY (1) MY148689A (fr)
NO (2) NO20051033L (fr)
NZ (1) NZ537611A (fr)
PA (1) PA8577901A1 (fr)
PE (1) PE20050128A1 (fr)
PL (1) PL375065A1 (fr)
PT (1) PT1531805E (fr)
RS (2) RS20080072A (fr)
SI (1) SI1531805T1 (fr)
TN (1) TNSN05022A1 (fr)
TW (2) TW200412944A (fr)
UA (1) UA82489C2 (fr)
WO (1) WO2004010993A1 (fr)
ZA (1) ZA200500196B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
CA2550215A1 (fr) 2003-12-23 2005-07-07 Astrazeneca Ab Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (fr) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
BRPI0708556A2 (pt) * 2006-03-06 2011-05-31 Teva Pharma composição de ezetimiba
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CN1994296B (zh) * 2006-08-02 2010-06-16 浙江京新药业股份有限公司 一种含有辛伐他汀的药物制剂
GB0713707D0 (en) 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
WO2009024889A2 (fr) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
AU2008337435A1 (en) * 2007-12-17 2009-06-25 Krka, Tovarna Zdravil, D.D., Novo Mesto Suspension comprising non-micronized ezetimibe micro-particles
US20090233898A1 (en) * 2008-03-11 2009-09-17 Glenmark Generics Ltd Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
EP2168573A1 (fr) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations contentant d'ézétimibe
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (fr) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Composition pharmaceutique comprenant ézétimide et simvastatine
WO2010066687A2 (fr) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Compositions comprenant une statine stabilisée
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
WO2011002424A2 (fr) * 2009-07-02 2011-01-06 Bilgic Mahmut Préparation pharmaceutique améliorant la solubilité et la stabilité
EP2448919A2 (fr) * 2009-07-02 2012-05-09 Mahmut Bilgic Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
WO2011002422A2 (fr) * 2009-07-02 2011-01-06 Bilgic Mahmut Formulation pharmaceutique améliorant la solubilité
EP2368543A1 (fr) * 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
KR101302243B1 (ko) * 2010-07-28 2013-09-02 씨제이제일제당 (주) 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
CN101978953A (zh) * 2010-10-11 2011-02-23 上海交通大学 基于易吸湿性辅料的固体制剂
EP2468258A1 (fr) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Procédé de préparation d'une composition pharmaceutique comportant un ingrédient actif pharmaceutiquement faiblement soluble
KR20130124551A (ko) 2011-02-02 2013-11-14 알파마 파머슈티컬스 엘엘씨 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
US9592296B2 (en) 2011-09-08 2017-03-14 Hexal Ag Pharmaceutical composition for oral administration with a statin
EP2844233B1 (fr) * 2012-05-01 2020-05-06 Althera Life Sciences, LLC Formulation de comprimé oral constituée d'une combinaison fixe de rosuvastatine et d'ézétimibe pour le traitement de l'hyperlipidémie et de maladies cardiovasculaires
WO2013166114A1 (fr) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Formulation de comprimé oral constituée d'une combinaison fixe d'atorvastatine et d'ézétimibe
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
CN103585146B (zh) * 2013-11-09 2015-04-01 北京中申专利科技有限公司 辛伐他汀的药物组合物
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
CN104306348B (zh) * 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
EP3370713A4 (fr) * 2015-11-06 2019-10-23 Gemphire Therapeutics Inc. Traitement de la dyslipidémie mixte
CN106937952A (zh) * 2016-01-04 2017-07-11 重庆华邦制药有限公司 依折麦布和辛伐他汀的制剂
EP3281649A1 (fr) * 2016-08-09 2018-02-14 Teleflex Lifesciences Formulation d'agent mouillant
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2019101150A1 (fr) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 Comprimé hs-25 et son procédé de préparation
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
AU1422388A (en) 1987-01-27 1988-08-10 Warner-Lambert Company Lipid regulating compositions
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2040865C (fr) 1990-05-15 2002-07-23 James L. Bergey Methode visant a prevenir, stabiliser ou reduire l'atherosclerose et reposant sur l'utilisation conjointe d'un medicament a effet hypocholesterolemiant et d'un inhibiteur de l'enzyme de conversion
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW223059B (fr) 1991-07-23 1994-05-01 Schering Corp
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
WO1993012765A1 (fr) * 1991-12-27 1993-07-08 Merck & Co., Inc. Dispositif d'administration et de dispersion de medicaments a liberation controlee
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
JPH06247854A (ja) * 1993-02-24 1994-09-06 Ss Pharmaceut Co Ltd アスコルビン酸含有組成物
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP0766667A1 (fr) * 1994-06-20 1997-04-09 Schering Corporation Composes d'azetidinone substitues utilises comme agent hypercholesterolemiant
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
MX9702175A (es) 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
DE69621952T2 (de) * 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
US6673831B1 (en) * 1996-04-17 2004-01-06 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
EP0904082A4 (fr) * 1996-04-17 2001-09-26 Merck & Co Inc Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
AU3667297A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Therapy for combined hyperlipidemia
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US6251852B1 (en) * 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235706B1 (en) * 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
WO1999066930A1 (fr) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions et methodes de traitement d'une cholesterolemie elevee
EP1089731A4 (fr) 1998-06-24 2003-06-18 Merck & Co Inc Compositions et methodes de traitement d'une cholesterolemie elevee
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
JP2000109882A (ja) * 1998-10-01 2000-04-18 Nof Corp 油性粉末、製造方法および用途
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU2866400A (en) 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
AU764048B2 (en) 1999-03-08 2003-08-07 Merck & Co., Inc. Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
NZ513965A (en) 1999-03-10 2004-04-30 G Method and composition for administering a cyclooxygenase-2 inhibitor
JP2000302672A (ja) * 1999-04-16 2000-10-31 Taisho Pharmaceut Co Ltd 咀嚼可能な被覆錠剤
JP3732039B2 (ja) * 1999-05-21 2006-01-05 三菱化学フーズ株式会社 錠剤用組成物
NZ516616A (en) 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
ATE293977T1 (de) * 1999-12-08 2005-05-15 Pharmacia Corp Nanopartikelzusammensetzungen enthaltend eplerenon
WO2001045676A2 (fr) 1999-12-20 2001-06-28 Schering Corporation Composition de dose orale a liberation prolongee
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
EE05442B1 (et) 2000-02-29 2011-08-15 Bristol-Myers Squibb Company V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
WO2002020457A1 (fr) * 2000-09-06 2002-03-14 Merck & Co., Inc. Sel d'acide ouvert dihydroxy de simvastatine
DE60106489T2 (de) * 2000-12-20 2005-10-13 Schering Corp. Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1354888T1 (sl) * 2000-12-28 2009-10-31 Kissei Pharmaceutical Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih
IL156585A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
IL156488A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
RS20100015A (sr) * 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
ATE369851T1 (de) 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa

Also Published As

Publication number Publication date
DE60320652T2 (de) 2009-06-10
MEP4708A (xx) 2010-02-10
HRP20080518A2 (hr) 2009-03-31
AR067030A2 (es) 2009-09-30
US7718643B2 (en) 2010-05-18
TNSN05022A1 (en) 2007-05-14
ES2303603T3 (es) 2008-08-16
EP1992343A1 (fr) 2008-11-19
AR040588A1 (es) 2005-04-13
DK1531805T3 (da) 2008-07-07
JP2008291034A (ja) 2008-12-04
EP1531805A1 (fr) 2005-05-25
PL375065A1 (en) 2005-11-14
IL166279A0 (en) 2006-01-15
NO20082156L (no) 2005-04-25
CN1671376A (zh) 2005-09-21
DE60320652D1 (de) 2008-06-12
PE20050128A1 (es) 2005-03-22
PT1531805E (pt) 2008-06-19
US20040126423A1 (en) 2004-07-01
EP1531805B1 (fr) 2008-04-30
RS20080072A (sr) 2008-11-28
CA2493076A1 (fr) 2004-02-05
US20090253675A1 (en) 2009-10-08
ATE393628T1 (de) 2008-05-15
KR20080070089A (ko) 2008-07-29
MY148689A (en) 2013-05-31
US20080275020A1 (en) 2008-11-06
CN101069684A (zh) 2007-11-14
BR0312933A (pt) 2005-07-12
RS50419B (sr) 2009-12-31
KR20050045993A (ko) 2005-05-17
WO2004010993A1 (fr) 2004-02-05
AU2003261217B2 (en) 2009-06-04
AU2009200768A1 (en) 2009-03-19
PA8577901A1 (es) 2004-10-08
RS20050061A (sr) 2007-09-21
NZ537611A (en) 2007-04-27
ME00207B (me) 2011-02-10
HK1080384A1 (en) 2006-04-28
GT200300149A (es) 2004-03-04
IL191348A0 (en) 2008-11-03
HRP20050081A2 (en) 2005-08-31
TW200906388A (en) 2009-02-16
US20070160666A1 (en) 2007-07-12
ECSP085573A (es) 2008-03-26
GT200300149AA (es) 2009-07-09
UA82489C2 (uk) 2008-04-25
MEP30808A (en) 2010-10-10
EA200500279A1 (ru) 2005-06-30
US7229982B2 (en) 2007-06-12
ZA200500196B (en) 2006-07-26
MXPA05001004A (es) 2005-05-16
ECSP055573A (es) 2005-04-18
IS7637A (is) 2005-01-10
GEP20084443B (en) 2008-08-10
JP2005538104A (ja) 2005-12-15
ME00008B (me) 2010-02-10
SI1531805T1 (sl) 2008-08-31
CR9767A (es) 2008-04-10
CN1310643C (zh) 2007-04-18
EA008888B1 (ru) 2007-08-31
NO20051033L (no) 2005-04-25
AU2003261217A1 (en) 2004-02-16
TW200412944A (en) 2004-08-01

Similar Documents

Publication Publication Date Title
TNSN05022A1 (en) Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
ATE372334T1 (de) Phenylpyrazolderivate als seh-inhibitoren
EP1268412B8 (fr) D riv s de bicyxloalkyle pontage substitution sulphonamido
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
BR0215405A (pt) Composições e processos de uso de collajolie
WO2005014539A3 (fr) Inhibiteurs nouveaux de l'hmg-coa reductase a base de pyrrole
CA2504735A1 (fr) Derives de phenylalanine utilises comme inhibiteurs de la dipeptidyl peptidase dans le traitement ou la prevention du diabete
AU2001274220A1 (en) Serine protease inhibitors
MY138289A (en) Pharmaceutical compositions
ES2194202T3 (es) Compuestos polimorfos.
UA74372C2 (uk) Інгібітори серинових протеаз, фармацевтична композиція на їх основі
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
PL351125A1 (en) Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
AU2002320317A1 (en) Novel mesogens and methods for their synthesis and use
WO2006071759A3 (fr) Derives de pyrazine fluorescents et methodes d'utilisation de ces derives a des fins d'evaluation de la fonction renale
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
WO2002085906A3 (fr) Phtalazinones
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
AU2001264065A1 (en) Serine protease inhibitors
EP1295879A4 (fr) Compositions medicinales contenant des derives de propenone
TR199903026T2 (xx) Aldoz red�ktaz inhibit�r� ve ace inhibit�r� i�eren farmas�tik bile�imler.
DE69420832D1 (de) Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
WO2005006860A3 (fr) Derives d'azole et procedes de fabrication associes